Teneligliptin hydrobromide

Chronic teneligliptin treatment at doses between 0.1 and 3.0 µmol/L does not reduce cell viability of HUVECs, but decreases HG-stress markers and increases heme oxygenase-1 (HMOX1) gene expression in HUVEC cells incubated under hyperglycemia. Also, chronic teneligliptin treatment improves proliferative capacities of HUVEC cells and endoplasmic reticulum (ER) function in HUVEC cells exposed to HG. Teneligliptin has antioxidant properties under NG in HUVECs, reducing ROS levels and initiating the transcriptional cascade of the antioxidant genes^[4].

HUVECs are seeded and allowed to attach overnight. Next day cells are exposed to one of three glucose experimental conditions with or without teneligliptin (at 0.1, 1.0 or 3.0 µmol/L) or sitagliptin (at 0.5 µmol/L): continuous normal glucose (NG-5 mmol/L) for 21 days; continuous high glucose (HG-25 mmol/L) for 21 days; and high-metabolic memory (HM-continuous HG for 14 days, followed by NG for the last 7 days). HUVECs are cultured during the 3 weeks changing the media each 48 h and without passaging the cells.

Teneligliptin attenuates body weight gain, fat accumulation, and serum insulin and triglyceride levels in the mouse model of postmenopausal obesity. Also improves glucose intolerance, but dose not affect insulin sensitivity. It attenuates chronic inflammation in perigonadal fat and hepatic steatosis in the mouse model of postmenopausal obesity. Teneligliptin increases locomotor activity in the dark phase and enhanced energy expenditure in postmenopausal obese mice^[2]. It is found that this compound attenuates lipogenesis in the liver by activating AMPK and downregulating the expression of genes involved in lipogenesis^[3].